Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Famotidine in non-erosive gastroesophageal reflux disease
NCT00141960Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Non-erosive Gastroesophageal Reflux Disease (NERD) comparing Famotidine with Placebo (2 arms). Primary endpoint: Rate of days with no heart burn in the treatment period. Started Sep 2005; status: completed.
02
Drugs
famotidine
03
Conditions
Non-erosive Gastroesophageal Reflux Disease (NERD)
Beyond the preview
Go deeper on NCT00141960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00141960.